Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of 2-dose BNT162b2 mRNA COVID-19 vaccine in Thai children 6 months to 4 years
TCTR20221018008Unknown
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoint: Immunogenicity of 2-dose BNT162b2 regimen. Status: unknown.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20221018008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221018008.